Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis
Status:
Unknown status
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if Bortezomib, known commercially as Velcade is
safe and tolerated at different dose levels (amounts) with high dose Cyclophosphamide to be
used as graft versus host disease prevention after reduced-intensity allogeneic hematopoietic
stem cell transplantation.